Hologic (NASDAQ:HOLX) Releases Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Hologic reported earnings of $1.08 per share, which exceeded analyst expectations of $1.05 by $0.03, with a revenue of $1.02 billion for the quarter.
• The company updated its Q4 2025 guidance to an EPS range of 1.090-1.120 and FY 2025 guidance to 4.230-4.260 EPS.
• Insider transactions revealed that Director Martin D. Madaus bought 5,445 shares at an average cost of $55.24, increasing his stake in the company.

Hologic (NASDAQ:HOLX - Get Free Report) announced its earnings results on Wednesday. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03, Zacks reports. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.06 earnings per share. Hologic updated its Q4 2025 guidance to 1.090-1.120 EPS and its FY 2025 guidance to 4.230-4.260 EPS.

Hologic Stock Performance

Shares of HOLX opened at $66.82 on Friday. Hologic has a 52-week low of $51.90 and a 52-week high of $84.67. The stock's 50-day simple moving average is $64.16 and its 200 day simple moving average is $62.83. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The stock has a market capitalization of $14.89 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.38 and a beta of 0.55.

Insiders Place Their Bets

In related news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Hedge Funds Weigh In On Hologic

An institutional investor recently raised its position in Hologic stock. Empowered Funds LLC boosted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 27.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,494 shares of the medical equipment provider's stock after purchasing an additional 3,790 shares during the quarter. Empowered Funds LLC's holdings in Hologic were worth $1,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HOLX. Stephens lowered their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Finally, Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $76.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.